Global Recombinant Vaccines Market Report and Forecast 2023-2031

Global Recombinant Vaccine Market Report and Forecast 2023-2031

Global Recombinant Vaccine Market Outlook

The value of the global recombinant vaccine market was USD 13.32 billion in 2022, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.91% during the forecast period of 2023-2031 to reach a value of USD 36.62 billion by 2031.

Recombinant Vaccine: Introduction

Recombinant vaccines are a type of vaccine that is created by inserting a piece of the pathogen's genetic material, typically DNA or RNA, into a carrier virus or bacteria. This carrier is then used to deliver the genetic material into the body, where it triggers an immune response and the body produces antibodies to fight off the pathogen.

Recombinant vaccines are considered a modern and innovative approach to vaccine development, as they offer several advantages over traditional methods of vaccine production. For example, they can be produced more quickly and with greater precision, and they have a lower risk of contamination or adverse reactions.

Recombinant vaccines have been developed for a variety of diseases, including influenza, hepatitis B, human papillomavirus (HPV), and COVID-19. They are considered a promising area of research for the development of new vaccines, particularly for emerging infectious diseases.

Recombinant Vaccine: Application and Uses

Recombinant vaccines are a type of vaccine that is produced through genetic engineering techniques. These vaccines are made using recombinant DNA technology to produce specific antigens, which are then used to stimulate the immune system and create an immune response against a specific pathogen. Recombinant vaccines have a variety of applications, including:

• Prevention of infectious diseases: Recombinant vaccines are used to prevent infectious diseases such as hepatitis B, human papillomavirus (HPV), and influenza.
• Treatment of cancer: Recombinant vaccines are being developed to treat cancer by stimulating the immune system to target and destroy cancer cells.
• Veterinary medicine: Recombinant vaccines are used to prevent diseases in animals, including livestock and pets.
• Biodefense: Recombinant vaccines are being developed to protect against potential bioterrorism threats, such as anthrax and smallpox.
• Allergies: Recombinant vaccines are used to treat allergies by desensitizing the immune system to specific allergens.

Overall, the use of recombinant vaccines is growing due to their safety, effectiveness, and versatility.

Global Recombinant Vaccine Market Segmentations

Market breakup by Type

• Live Attenuated
• Subunit

Market breakup by Disease Indication

• Hepatitis B
• Rotavirus
• Herpes Zoster
• Meningococcal B
• Others

Market by Distribution Channel

• Hospitals
• Vaccination Centres

Market by End User

• Paediatrics
• Adults
• Veterinary

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Global Recombinant Vaccine Market Scenario

The global recombinant vaccine market is expected to witness significant growth in the coming years owing to the increasing prevalence of infectious diseases, technological advancements in vaccine development, and the growing demand for vaccines across the world are some of the key factors driving the growth of the market.

Subunit vaccines are expected to hold the largest share of the market due to their lower risk of side effects and better immunogenicity.

Based on technology, the market is divided into conjugate vaccines, inactivated and subunit vaccines, and live attenuated vaccines. Conjugate vaccines are expected to hold the largest share of the market due to their high effectiveness against various diseases

Based on application, the market is divided into infectious diseases, cancer, and others. Infectious diseases are expected to hold the largest share of the market due to the high prevalence of infectious diseases across the world.

Based on end user, the market is divided into pediatrics, adults, and others. Pediatrics are expected to hold the largest share of the market due to the high demand for vaccines in children.

North America is expected to dominate the market due to the high adoption of advanced vaccines and the presence of major players in the region. However, the Asia Pacific region is expected to witness the highest growth in the coming years due to the increasing prevalence of infectious diseases and the growing demand for vaccines in the region.

Key Players in the Global Recombinant Vaccine Market

The report gives an in-depth analysis of the key players involved in the global recombinant vaccine market. The companies included in the market are as follows:

• GSK plc
• Pfizer Inc.
• Sanofi
• Walvax Biotechnology Co., Ltd. (Walvax)
• Dynavax Technologies Corporation
• Merck & Co., Inc.
• Novartis AG
• GC Biopharma
• Bayer AG
• Bharat Biotech
• Sartorius AG
• Serum Institute of India Pvt. Ltd.
• Bio Farma